Published in Breast Cancer Res on January 20, 2005
Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol (2009) 1.99
NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer (2008) 1.82
Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer (2007) 1.17
Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med (2011) 1.15
NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer (2007) 1.06
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia (2010) 1.04
Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer (2008) 0.95
Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration. Cell Death Differ (2014) 0.91
Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. Eur Radiol (2008) 0.89
Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer. Biol Chem (2008) 0.88
The current understanding of the molecular determinants of inflammatory breast cancer metastasis. Clin Exp Metastasis (2006) 0.84
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up. Br J Cancer (2007) 0.84
Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. PLoS One (2013) 0.83
Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. Int J Hyperthermia (2010) 0.81
Inflammatory breast cancer: New factors contribute to disease etiology: A review. J Adv Res (2013) 0.81
Atypical ubiquitin ligase RNF31: the nuclear factor modulator in breast cancer progression. BMC Cancer (2016) 0.78
In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene. J Cancer (2013) 0.78
Inflammatory Breast Cancer: A Case Report. Breast Care (Basel) (2009) 0.75
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
AP-1 in mouse development and tumorigenesis. Oncogene (2001) 3.93
Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol (2003) 3.27
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst (1985) 2.95
Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A (2003) 2.72
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69
RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res (2000) 2.48
The sonic hedgehog-patched-gli pathway in human development and disease. Am J Hum Genet (2000) 2.42
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res (2000) 2.13
Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer (1999) 2.05
WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene (2002) 2.02
Inflammatory breast cancer: a review. J Clin Oncol (1992) 1.93
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res (2002) 1.82
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res (2004) 1.77
Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol (2001) 1.73
Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer (1998) 1.71
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res (2001) 1.65
A novel human xenograft model of inflammatory breast cancer. Cancer Res (1999) 1.61
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol (1993) 1.58
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol (2004) 1.53
Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res (2001) 1.53
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res (2004) 1.51
Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer (1995) 1.51
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat (2004) 1.43
Update on the management of inflammatory breast cancer. Oncologist (2003) 1.36
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer (1989) 1.35
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer (2003) 1.33
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer (1998) 1.23
Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene (2002) 1.18
Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol (1997) 1.12
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene (2002) 1.10
Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer (1994) 1.08
Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer (2004) 1.06
Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer (1989) 1.06
Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int J Cancer (2002) 1.03
Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys (2003) 1.01
Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst (1993) 1.01
Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am (1995) 1.01
Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J (2002) 1.00
Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat (2000) 0.97
Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer (1987) 0.93
Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys (1989) 0.91
p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer (1994) 0.91
Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant (2004) 0.87
Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer (1994) 0.85
Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res (1992) 0.84
[Breast cancers in the evolutive phase]. Rev Prat (1978) 0.84
Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer (2002) 0.84
Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer (1981) 0.84
Two prognostic groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res (2003) 0.84
Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer (2002) 0.83
Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer (1994) 0.83
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer (1995) 0.82
Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Radiother Oncol (1986) 0.81
Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer (1999) 0.80
Secondary inflammatory breast cancer: treatment options. South Med J (1988) 0.80
Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors. Breast Cancer Res Treat (1990) 0.79
Inflammatory breast carcinoma: comparison of survival of those diagnosed clinically, pathologically, or with both features. Am Surg (1998) 0.79
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res (2003) 2.37
Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol (2008) 2.16
A six-gene signature predicting breast cancer lung metastasis. Cancer Res (2008) 2.09
SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res (2002) 2.09
Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer (2003) 1.95
Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res (2003) 1.84
NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer (2008) 1.82
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat (2012) 1.77
Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res (2004) 1.77
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med (2011) 1.68
Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol (2012) 1.67
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer (2007) 1.62
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res (2009) 1.61
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics (2007) 1.59
Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther (2012) 1.55
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol (2009) 1.47
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res (2012) 1.47
Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res (2011) 1.47
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res (2007) 1.46
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer (2013) 1.40
RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res (2004) 1.40
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer (2010) 1.31
Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene (2002) 1.31
Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res (2004) 1.24
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol (2008) 1.20
Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res (2004) 1.18
Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol (2007) 1.18
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol (2007) 1.16
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet (2012) 1.13
Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol (2007) 1.12
Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res (2010) 1.12
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci (2008) 1.11
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res (2011) 1.11
A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res (2008) 1.10
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene (2002) 1.10
Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. Cancer Res (2010) 1.08
Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J Natl Cancer Inst (2011) 1.07
Unclassified variants identified in BRCA1 exon 11: Consequences on splicing. Genes Chromosomes Cancer (2008) 1.07
Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer (2010) 1.07
Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet (2005) 1.04
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther (2011) 1.03
Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet (2010) 1.01
Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol (2002) 1.00
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol (2008) 1.00
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res (2009) 0.99
High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. Endocr Relat Cancer (2007) 0.99
Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy (2014) 0.99
PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer (2013) 0.99
Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP. J Med Genet (2010) 0.98
Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. J Urol (2006) 0.98
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One (2010) 0.97
Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med (2010) 0.97
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. Mol Cancer (2011) 0.95
DNA repair gene expression and risk of locoregional relapse in breast cancer patients. Int J Radiat Oncol Biol Phys (2010) 0.95
Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis. Clin Exp Metastasis (2007) 0.94
Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis (2003) 0.94
Multiple sequence variants of BRCA2 exon 7 alter splicing regulation. J Med Genet (2012) 0.94
miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer (2013) 0.93
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol (2010) 0.93
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer (2008) 0.92
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. Int J Cancer (2005) 0.91
Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum (2005) 0.91
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat (2010) 0.91
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther (2010) 0.90
Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Res Treat (2011) 0.90
Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma. Anticancer Res (2005) 0.89
Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas (2006) 0.89
Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res (2008) 0.88
Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res (2003) 0.87
Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett (2004) 0.86
Identification of a three-gene expression signature of poor-prognosis breast carcinoma. Mol Cancer (2004) 0.86
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev (2005) 0.86
Similar NF-κB gene signatures in TNF-α treated human endothelial cells and breast tumor biopsies. PLoS One (2011) 0.86
Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. Am J Pathol (2011) 0.85
Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. J Urol (2004) 0.85